BPAs, namely recombinant activated factor VII (eptacog alfa) and activated prothrombin complex concentrates are commonly used for the bleeding treatment of patients with congenital hemophilia A and anti-FVIII inhibitor; they are able to overcome the interference of the inhibitor on the coagulation pathway, inducing thrombin generation regardless of the presence of FVIII [18]. The gene discussed is F7; the disease is hemophilia A.